



RAVIMIAMET

Barbara Ruepp
ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern
SWITZERLAND

16.09.2024 nr RKU-4/70

DECISION

to grant authorisation for clinical trial on the basis of Regulation (EU) No 536/2014 of the European Parliament and of the council

State Agency of Medicines has received the application from sponsor ETOP IBCSG Partners Foundation on 21.05.2024 to conduct a clinical trial under the conditions stipulated in Regulation (EU) No 536/2014 art 5 (1) and § 99¹ (1) of Estonian Medicinal Products Act (MPA).

Based on art 8 of Regulation (EU) No 536/2014, considering the aspects covered by Part I and Part II of the assessment report, on the basis of § 99⁶ section 1 p 2 and (3) of Medicinal Product Act

State Agency of Medicines has decided to give the approval to conduct the clinical study protocol no ETOP25-23 ADOPT-lung under the following conditions:

protocol no: ETOP25-23 ADOPT-lung (Version 1.1, dated August 15, 2024)

full title of the trial: ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC

sponsor of the trial: ETOP IBCSG Partners Foundation

number of subjects in Estonia: 30

starting date: October 2024

principal investigators and study locations:

- Dr Kersti Oselin, North Estonia Medical Centre Foundation, J. Sütiste tee 19, 13419 Tallinn, Estonia

The addressee may file a challenge with State Agency of Medicines within 30 days as of the day when the addressee became or should have become aware of the decision as prescribed in Code of Administrative Procedure § 71(1). If the addressee wishes to have the decision to

annulled by the administrative court, he or she may submit a complaint to the Tartu Administrative Court as prescribed in § 7(1) and § 46(1) of the Code of Administrative Court Procedure within 30 days after the date on which the decision was notified to the applicant.

(digitally signed)

Katrin Kiisk
Director General